Do you want to link to this Amgen Site outside the UK and leave amgeninflammation.co.uk?
YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.
Natural killer (NK) cells, representing 5–20% of circulating lymphocytes, are the predominant innate lymphocyte subsets that mediate antitumor and antiviral responses. Earlier it was believed that NK cells develop only within the bone marrow; however, it has now been demonstrated that the development and maturation of NK cells may also take place in the secondary lymphoid tissues such as tonsils, spleen, and lymph nodes. The development of NK cells in the bone marrow and lymph nodes can be classified into six distinct stages (stages 1–6).1
NK cells do not require prior antigen exposure to mediate their effector functions;1 however, after activation, they secrete several cytokines such as IFN-γ, TNF-α, GM-CSF, IL-10, IL-5, and IL-13 and chemokines such as MIP-1α, MIP-1β, IL-8, and RANTES, that can modulate the function of other innate and adaptive immune cells.2 IL-10 and IL-18 together have the potential to induce NK cell proliferation, cytotoxic function, and IFN-γ production. The cytokines secreted by NK cells significantly boost the antitumor immunity.2
In addition to their antitumor and antiviral functions, NK cells also mediate regulatory functions of myeloid or lymphoid cells by producing cytokines or via direct cell-cell contact in a receptor-ligand interaction-dependent manner.1 Though typically considered to be a part of the innate immune system, NK cells also possess memory cell–like features.2
GM-CSF: granulocyte-macrophage colony-stimulating factor; IFN-γ: interferon gamma; IL: interleukin; MIP: macrophage inflammatory protein; RANTES: regulated on activation, normal T cell expressed and secreted; TNF: tumor necrosis factor.
Adverse events should be reported. Reporting forms and information can be found for the UK at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or for Ireland at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events and product complaints should also be reported to Amgen Limited on +44 (0)1223 436441 (UK and Northern Ireland) or Freephone 1800 535 160 (Ireland)